In addition to findings in preclinical models, we also described how the IDH1 mutation could act as a therapeutic drug that simultaneous targets the glycolysis and glutaminolysis pathways to improve survival in a GBM patient (11) (Figure 7). The gene discussed is IDH1; the disease is glioblastoma.